Surrozen, Inc. Schedules Third Quarter 2026 Earnings Announcement
Surrozen, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 11, 2026.
Stocks · News reference
Surrozen Says FDA Cleared IND For SZN-8141 In Diabetic Macular Edema, Triggering About $95.1M Second Tranche Of Private Placement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen, Inc. (NASDAQ: SRZN) announced the closing of its second tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by FDA clearance of the IND application for SZN-8141 on October 2, 2026. The company now has cash runway into 2029 to advance its ophthalmology pipeline, including the DUET Phase 1b/2a study of SZN-8141 for diabetic macular edema and initial clinical development of SZN-8143. First patient dosing in the DUET study is expected in Q4 2026, with initial data anticipated in H2 2027.
8-K filing — Surrozen, Inc./DE (SRZN)
Filed: 2026-10-20 AccNo: 0001193125-26-426828 Size: 199 KB Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.